Cargando…
Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials
BACKGROUND: As a new generation antihistamine, fexofenadine has been widely used in allergic diseases. However, there is still a lack of collective evidence regarding the antihistamine effects and safety profiles of fexofenadine relative to other antihistamine drugs and placebo. Therefore, we aimed...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884918/ https://www.ncbi.nlm.nih.gov/pubmed/31783781 http://dx.doi.org/10.1186/s40360-019-0363-1 |
_version_ | 1783474649433112576 |
---|---|
author | Huang, Cheng-zhi Jiang, Zhi-hui Wang, Jian Luo, Yue Peng, Hua |
author_facet | Huang, Cheng-zhi Jiang, Zhi-hui Wang, Jian Luo, Yue Peng, Hua |
author_sort | Huang, Cheng-zhi |
collection | PubMed |
description | BACKGROUND: As a new generation antihistamine, fexofenadine has been widely used in allergic diseases. However, there is still a lack of collective evidence regarding the antihistamine effects and safety profiles of fexofenadine relative to other antihistamine drugs and placebo. Therefore, we aimed to systematically evaluate the antihistamine effects and safety of fexofenadine. METHODS: An electronic literature search of randomized controlled trials (RCTs) was performed using Embase, Cochrane and PubMed from establishment to January 1st, 2018. RCTs comparing the antihistamine effects or safety (adverse events, sedative effects, and cognitive/psychomotor function) of fexofenadine with either other antihistamines or placebo for healthy subjects and patients with allergy were selected. RESULTS: Fifty-one studies of 14,551 participants met the inclusion criteria. When compared with the first-generation antihistamines, fexofenadine produced significantly lower adverse events frequency (OR = 0.446; 95% CI: 0.214 to 0.929, P = 0.031), significantly lower sedative effects frequency (OR = 0.265; 95% CI: 0.072 to 0.976, P = 0.046) and significantly less change of all cognitive/psychomotor function. When compared with the second-generation antihistamines, fexofenadine produced significantly marginal sedative effects (OR = 0.59; 95% CI, 0.38 to 0.93; P = 0.02) and significantly less change of most of the cognitive/psychomotor function. When compared with placebo, fexofenadine produced more significant antihistamine effects. CONCLUSIONS: Fexofenadine has a positive antihistamine effect, which is probably no worse than the second-generation antihistamines. Fexofenadine probably has a favorable safety profile, which is more likely better than that of the first-generation antihistamines. There is lack of data to support that fexofenadine has a better overall safety profile compared to the second-generation antihistamines, however, some presently available evidence on sedative effects and certain aspects of cognitive/psychomotor function favors fexofenadine. Therefore, fexofenadine may be worthy of recommendation for safety related workers. |
format | Online Article Text |
id | pubmed-6884918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68849182019-12-03 Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials Huang, Cheng-zhi Jiang, Zhi-hui Wang, Jian Luo, Yue Peng, Hua BMC Pharmacol Toxicol Research Article BACKGROUND: As a new generation antihistamine, fexofenadine has been widely used in allergic diseases. However, there is still a lack of collective evidence regarding the antihistamine effects and safety profiles of fexofenadine relative to other antihistamine drugs and placebo. Therefore, we aimed to systematically evaluate the antihistamine effects and safety of fexofenadine. METHODS: An electronic literature search of randomized controlled trials (RCTs) was performed using Embase, Cochrane and PubMed from establishment to January 1st, 2018. RCTs comparing the antihistamine effects or safety (adverse events, sedative effects, and cognitive/psychomotor function) of fexofenadine with either other antihistamines or placebo for healthy subjects and patients with allergy were selected. RESULTS: Fifty-one studies of 14,551 participants met the inclusion criteria. When compared with the first-generation antihistamines, fexofenadine produced significantly lower adverse events frequency (OR = 0.446; 95% CI: 0.214 to 0.929, P = 0.031), significantly lower sedative effects frequency (OR = 0.265; 95% CI: 0.072 to 0.976, P = 0.046) and significantly less change of all cognitive/psychomotor function. When compared with the second-generation antihistamines, fexofenadine produced significantly marginal sedative effects (OR = 0.59; 95% CI, 0.38 to 0.93; P = 0.02) and significantly less change of most of the cognitive/psychomotor function. When compared with placebo, fexofenadine produced more significant antihistamine effects. CONCLUSIONS: Fexofenadine has a positive antihistamine effect, which is probably no worse than the second-generation antihistamines. Fexofenadine probably has a favorable safety profile, which is more likely better than that of the first-generation antihistamines. There is lack of data to support that fexofenadine has a better overall safety profile compared to the second-generation antihistamines, however, some presently available evidence on sedative effects and certain aspects of cognitive/psychomotor function favors fexofenadine. Therefore, fexofenadine may be worthy of recommendation for safety related workers. BioMed Central 2019-11-29 /pmc/articles/PMC6884918/ /pubmed/31783781 http://dx.doi.org/10.1186/s40360-019-0363-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Huang, Cheng-zhi Jiang, Zhi-hui Wang, Jian Luo, Yue Peng, Hua Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials |
title | Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials |
title_full | Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials |
title_fullStr | Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials |
title_full_unstemmed | Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials |
title_short | Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials |
title_sort | antihistamine effects and safety of fexofenadine: a systematic review and meta-analysis of randomized controlled trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884918/ https://www.ncbi.nlm.nih.gov/pubmed/31783781 http://dx.doi.org/10.1186/s40360-019-0363-1 |
work_keys_str_mv | AT huangchengzhi antihistamineeffectsandsafetyoffexofenadineasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jiangzhihui antihistamineeffectsandsafetyoffexofenadineasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT wangjian antihistamineeffectsandsafetyoffexofenadineasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT luoyue antihistamineeffectsandsafetyoffexofenadineasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT penghua antihistamineeffectsandsafetyoffexofenadineasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |